Scheiblecker Lisa, Kollmann Karoline, Sexl Veronika
Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.
Pharmaceuticals (Basel). 2020 Nov 24;13(12):418. doi: 10.3390/ph13120418.
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are frequently deregulated in cancer and signify vulnerable nodes and potential therapeutic targets. We here focus on the cell cycle kinase CDK6 and on the MAPK pathway and on their interplay. We also provide an overview on clinical studies examining the effects of combinational treatments currently explored for several cancer types.
尽管有了靶向治疗和新型抑制剂的发展，但癌症仍然是一种未被攻克的疾病。耐药机制迅速出现，迫切需要替代治疗方案，药物联合使用可能部分满足这一需求。蛋白激酶作为信号枢纽，在癌症中经常失调，是脆弱节点和潜在治疗靶点。我们在此关注细胞周期激酶CDK6和丝裂原活化蛋白激酶（MAPK）信号通路及其相互作用。我们还概述了目前针对几种癌症类型探索联合治疗效果的临床研究。
